Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Artesunate→

Artesunate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
88495-63-0
Molecular formula
C19H28O8
Molecular weight
384.4 g/mol
Drug class
Artemisinin-derivative antimalarial
Mechanism of action
The endoperoxide bridge is likely cleaved through reaction with haem in infected erythrocytes, generating reactive radicals that alkylate essential parasite proteins; additional parasite targets have also been proposed.
Indications / reported uses
  • Malaria, including severe malaria when an appropriate parenteral formulation is used

Sources: WHO prequalification product information · US FDA prescribing information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Artesunate Environmental Risk Assessment (ERA) (the Artesunate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.